Technology
Panthera joins Parexel’s Site Alliance Vaccine Network
In October 2024, Panthera Biopartners announced that Parexel has confirmed its inclusion in the Parexel Site Alliance Vaccine Network.
SK bioscience completes IDT Biologika acquisition
In October 2024, SK bioscience announced the successful completion of its acquisition of a controlling stake in IDT Biologika. This follows the announcement
Vaccine delivery vehicle to improve access in Samoa
UNICEF announced in September 2024 that it is working with Australia and Samoa to improve access to vaccinations in Samoa. To this end, an innovative
MSD Animal Health expands NOBIVAC NXT platform for cats
MSD Animal Health announced in September 2024 that it is expanding the newly USDA-approved NOBIVAC NXT vaccine platform to include a best-in-class
Evaxion launches enhanced AI-Immunology platform
Evaxion Biotech announced the launch of an enhanced version of its clinically validated AI-Immunology platform in September 2024, with an update
Nanoparticle platform boosts range of vaccine candidates
Researchers in Science Advances present their work developing a “highly modular saponin-based nanoparticle platform”. The platform incorporates Toll-like receptor agonists (TLRas), including TLR1/2a, TLR4a, and TLR7/8a adjuvants and their mixtures. These induce...
Phylex “on track” with Nipah virus vaccine research
In August 2024 Phylex Biosciences announced the publication of a preprint presenting research into the immunogenicity of its Nipah mRNA nanoparticle vaccine candidate. The paper, co-authored with CDC scientists, found that the vaccine elicited a “robust” neutralising...
AAHI and Afrigen partner on adjuvants for sub-Saharan Africa
In August 2024 the Access to Advanced Health Institute (AAHI) announced an expanded partnership with Afrigen Biologics to develop effective vaccines using AAHI’s innovative adjuvant formulations in sub-Saharan Africa. This develops a longstanding joint commitment that...
Valneva and LimmaTech partner on Shigella vaccine
In August 2024 Valneva and LimmaTech announced that they have entered a strategic partnership and exclusive licensing agreement for the development, manufacture, and commercialisation of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against...
WHO prequalification status for Biological E’s nOPV2
Biological E announced in July 2024 that WHO has granted prequalification status to the company’s Novel Oral Polio Vaccine type 2 (nOPV2). Biological E describes this as a “monumental stride” towards global polio eradication, celebrating the 10th Biological E vaccine...
ApiJect Injector shows favourable environmental profile
ApiJect announced in July 2024 that a peer reviewed study comparing the environmental footprint of the company’s prefilled injection device to traditional glass syringe options found a “substantial difference” in favour of the Prefilled Injector. The study identified...
GSK and Flagship announce portfolio collaboration
GSK and Flagship Pioneering announced in July 2024 that they have entered a collaboration to discover and develop a portfolio of “transformational” medicines and vaccines, starting in respiratory and immunology. The agreement will combine GSK’s “disease area expertise...
Fighting TB: a multi-epitope-based subunit vaccine
An article in Scientific reports in July 2024 describes the “pressing need” for novel and safe vaccines that provide “robust immune defence and have various applications” against tuberculosis. The authors apply an immunoinformatic strategy to generate an adequate...
WHO introduces global open access MeDevIS platform
WHO announced in July 2024 that its online open access clearing house, MeDevIS (Medical Devices Information System), is being publicly released following a consultation period with WHO Member States. The platform is designed to support governments, regulators, and...
mRNA in Japan: Moderna and Mitsubishi Tanabe join forces
Moderna and Mitsubishi Tanabe Pharma Corporation announced in July 2024 that they have entered a joint agreement regarding the co-promotion of Moderna’s mRNA respiratory vaccine portfolio in Japan. This includes Moderna’s COVID-19 vaccines, Spikevax. Through the...
CEPI to support Apriori Bio’s Octavia AI platform
In July 2024 CEPI announced an award of US $1.1 million to support Apriori Bio in advancing its biology-informed artificial intelligence platform Octavia. Octavia is intended to protect humanity against rapidly evolving viruses through the design of variant-resilient...
HilleVax to discontinue infant norovirus vaccine development
HilleVax announced in July 2024 that topline data results from NEXT-IN1, a Phase IIb trial of HIL-214, reveal a failure to meet primary and secondary efficacy endpoints. This trial in infants around 5 months old at time of initial vaccination was conducted after a...
Merck and Afrigen announce mRNA technology MoU
Merck’s Life Science business sector and Afrigen Biologics announced in July 2024 that they have entered a non-binding Memorandum of Understanding (MoU) to support the development of an mRNA vaccine technology platform. The collaboration will seek to advance...
GSK and CureVac announce mRNA licensing agreement
In July 2024, GSK and CureVac announced that they have “restructured” an existing collaboration into a new licensing agreement to allow both companies to “prioritise investment and focus their respective mRNA development activities”. The two companies have been...
HHS provides $176 million for Moderna mRNA influenza efforts
The US Department of Health and Human Services (HHS) announced that through BARDA, part of the Administration for Strategic Preparedness and Response (ASPR), it will provide around $176 million to Moderna to support the development of an mRNA-based pandemic influenza...
